We are very pleased to announce that Shannon J. McCall, MD, Vice Chair of Translational Research in the Department of Pathology, has been promoted to Associated Professor with Tenure effective March 1, 2020.
Dr. McCall obtained her MD from Duke University and remained at Duke for Anatomic and Clinical Pathology Residency, where she was elected to Alpha Omega Alpha and served as Chief Resident. Since joining the faculty, she has authored 93 peer-reviewed publications focused on gastrointestinal malignancies, biobanking and precision cancer medicine. She is an international thought leader in human sample biobanking who has served on multiple National Institutes of Health (NIH) Study Sections and presented her work in China, Great Britain, Germany and Canada. She holds leadership roles on relevant committees within the College of American Pathologists (CAP), the International Society of Biological and Environmental Repositories (ISBER) and the American Association for Cancer Research (AACR).
Dr. McCall has served as a collaborator with other Duke faculty members on numerous NIH and Department of Defense grants, and she served as principal investigator on Duke’s Cancer Genome Atlas (TCGA) contract from the National Cancer Institute (NCI). She continues to serve as the principal investigator for Duke’s participation in the NCI’s Clinical Proteomics Tumor Analysis Consortium (CPTAC) and the AACR’s Genomics Evidence Neoplasia Information Exchange (GENIE) project. She has obtained industry-funding and non-profit organizational funding for multiple projects and led multiple supplemental projects arising from NCI awards. In 2019, she was awarded a five-year, multimillion-dollar UM1 grant to establish Duke University as the Southern Division for the NCI’s Cooperative Human Tissue Network (CHTN).
Her contributions to Duke University include co-creating the BioRepository & Precision Pathology Center (which she has directed since 2013), directing the Pathology Third Year Medical Student Study Program, and co-creating Duke’s Precision Cancer Medicine Initiative in partnership with the Duke Cancer Institute. The latter includes support for Duke’s weekly Molecular Tumor Board in which data-driven approaches are used to evaluate late-stage cancer patients for novel therapies or participation in clinical trials. As the Vice Chair of Translational Research for the Department of Pathology, she most recently brokered the creation of the new Division of Artificial Intelligence and Computational Pathology in partnership with Duke University’s Vice President for Research Dr. Lawrence Carin and Duke’s ‘AI Health’ program.